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Abstract
Background: Artemisinin-based combination therapy (ACT) is the treatment of choice for uncomplicated falciparum malaria.
Artemether-lumefantrine (AL), a fixed dose co-formulation, has recently been approved for marketing in India, although it is not
included in the National Drug Policy for treatment of malaria. Efficacy of short course regimen (4 × 4 tablets of 20 mg artemether
plus 120 mg lumefantrine over 48 h) was demonstrated in India in the year 2000. However, low cure rates in Thailand and better
plasma lumefantrine concentration profile with a six-dose regimen over three days, led to the recommendation of higher dose
globally. This is the first report on the therapeutic efficacy of the six-dose regimen of AL in Indian uncomplicated falciparum
malaria patients. The data generated will help in keeping the alternative ACT ready for use in the National Programme as and
when required.
Methods: One hundred and twenty four subjects between two and fifty-five years of age living in two highly endemic areas of
the country (Assam and Orissa) were enrolled for single arm, open label prospective study. The standard six-dose regimen of
AL was administered over three days and was followed-up with clinical and parasitological evaluations over 28 days. Molecular
markers msp-1 and msp-2 were used to differentiate the recrudescence and reinfection among the study subjects. In addition,
polymorphism in pfmdr1 was also carried out in the samples obtained from patients before and after the treatment.
Results: The PCR corrected cure rates were high at both the sites viz. 100% (n = 53) in Assam and 98.6% (n = 71) in Orissa.
The only treatment failure case on D7 was a malnourished child. The drug was well tolerated with no adverse events. Patients
had pre-treatment carriage of wild type codons at positions 86 (41.7%, n = 91) and 184 (91.3%, n = 91) of pfmdr1 gene.
Conclusion: AL is safe and effective drug for the treatment of acute uncomplicated falciparum malaria in India. The
polymorphism in pfmdr1 gene is not co-related with clinical outcome. However, treatment failure can also occur due to
incomplete absorption of the drug as is suspected in one case of failure at D7 in the study. AL can be a viable alternative of
artesunate plus sulphadoxine/pyrimethamine (AS + SP), however, the drug should be used rationally and efficacy needs to be
monitored periodically.
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Resistance in Plasmodium falciparum to commonly used
anti-malarial drugs, especially chloroquine, is being
increasingly recognized in India [1]. More than 80% of
the therapeutic efficacy studies (n = 143) conducted from
2001–07 indicate failure to chloroquine beyond cut off
level of 10% (unpublished data). WHO recommends use
of artemisinin-based combination therapy (ACT) to coun-
ter the development of resistance in P. falciparum to anti-
malarials and to achieve rapid resolution of parasitaemia
and morbidity [2]. Accordingly, the National drug policy
has been revised in India in favor of using ACT. Although
at present artesunate plus sulphadoxine/pyrimethamine
(AS+SP) has been recommended for the treatment of
uncomplicated falciparum malaria, data are also being
generated for new fixed dose combinations to help the
National Programme to adopt the most effective, easy to
administer, feasible, safe and cost-effective strategy.
Artemether-lumefantrine (AL) is a co-formulation of arte-
mether and lumefantrine (an aryl alcohol related to qui-
nine, mefloquine and halofantrine). The reported 28 day
cure rate for six- dose regimen ranges between 89.6 and
98.5% and 42 day cure rate ranges between 87 and 94.8%
[3-5]. In India, 28 day cure rate of 94.5% was reported by
Kshirsagar et al [6] with four dose regimen (4 × 4 tablets
of 20 mg artemether plus 120 mg lumefantrine over 48 h)
in a double-blind comparative study with chloroquine in
falciparum malaria. However, in Thailand this regimen
resulted in failure rates of 20%, which reduced to 5% by
using a six-dose regimen [7]. Therefore, high efficacy
observed earlier in South-East Asia (SEA) with low dose,
including India, may be due to background immunity
which may not be sustainable. In addition, the better
plasma lumefantrine concentration profiles have been
observed with high dose regimen [8].
The present study was conducted to evaluate the efficacy
of AL with six-dose regimen in two endemic regions of
India following the WHO (2003) therapeutic efficacy pro-
tocols [9].
Methods
Study site and design
The study was conducted in Kamrup district (Assam) in
north-eastern India and Keonjhar district (Orissa) in east-
ern part of India (Figure 1), where the annual parasite
incidence in 2006 were 2.7 and 17.5, respectively. At both
the sites, malaria transmission is perennial with the pre-
dominance of falciparum malaria (76.3% in Kamrup and
96.5% in Keonjhar).
It was an open label, single arm prospective trial based on
the therapeutic efficacy protocols of WHO [9]. The pri-
mary end point was 28-day cure rate. Secondary end
points included proportion of aparasitaemic patient on
days 1, 2 and 3 and post-treatment gametocyte carriage.
The study was approved by the Ministry of Health, Govt.
of India and the Ethics Committee of National Institute of
Malaria Research.
Patients
Patients with microscopically confirmed P. falciparum
malaria (asexual parasites 1,000–100,000/μl), with fever
(axillary temperarture, ≥ 37.5°C) or history of fever in
preceeding 24 h, who gave voluntary consent were
enrolled in local clinics. Pregnant or lactating women and
children under 5 kg bodyweight were excluded. Patients
with other febrile conditions, danger signs [9] or severe
malaria were also excluded.
Procedures
After obtaining the informed written consent from
patients or guardian, a medical history including present-
ing symptoms, current medications and previous anti-
malarial use was obtained. A complete physical examina-
tion was performed and case record form was completed
for each patient. Clinical history, examination and other
investigations were all recorded. Blood was collected for
parasitology and molecular biology studies.
Treatment
Patients were given AL (Coartem®, Novartis Pharmaceuti-
cals Corporation, Suffern, New York, USA; Batch No.:
F0443) according to body weight with biscuits and glass
of water. Patients weighing 10–15 kg received one tablet
(20 mg artemether plus 120 mg lumefantrine) per dose,
those weighing 15–25 kg received two, those of 25–35 kg
received three, and those >35 kg received four tablets. In
total, six doses were administered at hours 0, 8, 24, 36, 48,
and 60. Treatment with both the doses, every day, was
directly observed by the study team. No patient had vom-
iting and, therefore, re-administration of the drug was not
required.
Follow-up
All the patients were followed-up on days 1, 2, 3, 7, 14, 21
and 28. On each day, in addition to physical examination,
blood smears for malaria parasites and filter paper spot
samples for genotyping were obtained.
Laboratory methods
Parasite counts were done on Giemsa-stained thick films
and the number of parasites per 200 WBC was counted by
light microscopy, by microscopists with 10–15 years of
experience. Assuming a WBC count to be 8,000/μl, para-
sitaemia was calculated and expressed as per μl. A thick
smear was regarded as negative on initial review if no par-
asites were seen in 100 high power fields and 10% of pos-
itive and negative slides were cross-checked.Page 2 of 8
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Genomic DNA of parasite was isolated from filter paper
using QIAamp DNA Blood kit (Qiagen, Valencia, Califor-
nia, USA) according to the manufacturer's instructions
and used for a polymerase chain reaction (PCR). To dis-
tinguish between recrudescent and new infections PCR
method was used to analyse polymorphisms in the mero-
zoite surface protein (MSP) genes, msp-1 and msp-2 in pre-
treatment and post-treatment isolates following the
method described earlier [10].
Two fragments of pfmdr1, one spanning codons 71–242,
and other covering 945–1308 codons were amplified to
analyze SNP's at codons 86, 184, 1034, 1042 and 1246. In
Study sitesFigure 1
Study sites.
Table 1: Primer sequences and PCR conditions for pfmdr1 amplification
Fragment amplified Primer name Product size (bp) Primer sequence Cycling conditions*
Pfmdr1 fragment 1
(codons 86&184)
Pf 86 677 AGAGGTTGAAAAAGAGTTGAAC 94°C for 30 sec; 56°C for 45 sec;
and 72°C for 1 min, 40 cycles
Pr 86 TTCTTATTCCCATTAAAGCCTC
Nf 86 471 CCGTTTAAATGTTTACCTGCAC 94°C for 30 sec; 55°C for 1 min;
Nr86 AACGCAAGTAATACATAAAGTCA and 72°C for 30 sec, 30 cycles
Pfmdr1 fragment 2 Pf 1034 1092 GTGTATTTGCTGTAAGAGCTAG 94°C for 30 sec; 57°C for 1 min;
(codons1034,1042&1246) Pr 1034 CATATGGTCCAACATTTGTATC and 72°C for 1 min, 40 cycles
Nf1034 950 GATGAAATGTTTAAAGATCCAAG 94°C for 30 sec; 56°C for 1 min;
Nr1034 TCATCTATAGCAGCAAACTTAC and 72°C for 1 min, 35 cycles
Note: *In each PCR, initial denaturation was at 94°C for 15 min, and final extension at 72°C for 15 minPage 3 of 8
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region-spanning codons 44–177. Primers and cycling
conditions used for amplification of fragments of pfmdr1
are shown in Table 1, while the strategy followed for pfcrt
analysis was same as described earlier [11]. The PCR prod-
ucts were purified from the agarose gel by using gel extrac-
tion Kit (Mdi, Membrane Technology, India). About 50–
250 ng of the purified DNA was used for sequencing PCR
using ABI Big Dye Terminator Reaction Ready Kit Version
3.1(PE Applied Biosystems, California, USA). The
sequencing PCR was performed in a volume of 20 μl with
1 μl of Terminator Ready Reaction Mix (TRR), 3.2 pmol of
gene-specific primer. Cycling conditions for the sequenc-
ing PCR included 25 cycles of denaturation at 96°C for 10
sec, annealing at 50°C for 5 sec, and extension at 60°C for
4 min. Templates were purified and sequenced on an ABI
Prism 310 Genetic Analyzer (PE Applied Biosystems).
Statistical analysis
Data was entered in WHO TM software. The cumulative
risk of failure was assessed by survival analysis with the
Kaplan Meier method.
Results
Patients were screened between July and October 2007 at
Kamrup District, Assam and August to October 2007 at
Keonjhar District, Orissa. A total of 124 patients were
enrolled. Baseline characteristics and age category is
shown in table 2. One patient was lost to follow-up due to
movement away from site and could not be traced. One
was withdrawn on D28 since it was classified as reinfec-
tion by PCR. End point was reached in 122 cases (Figure
2). No discrepancies (>30% variation in count) were
found on crosschecking. Response to treatment was clas-
sified according to WHO guidelines into early treatment
failure (ETF), late treatment failure (LTF) and adequate
clinical and parasitogical response (ACPR). PCR-corrected
and uncorrected cure rates were determined by per proto-
col method using WHO software. In addition, Kaplan
Meier analysis was done where loss to follow-up, with-
drawals or reinfections were censored on last day of fol-
low-up. The PCR-uncorrected cure rates by per protocol
analysis was 100% and 97.1% in Assam and Orissa
respectively (Figure 3). The parasite clearance was rapid at
both the sites and complete clearance of parasiaemia
within 48 h was observed in 79.2 and 90.1% patients in
Assam and Orissa, respectively. The mean parasite clear-
ance time (PCT) was 50.8 ± 11.2 h and 34.1 ± 16.1 h in
Assam and Orissa respectively. Proportion of patients
with gametocytes at enrollment was 18.8% and 34.2%
respectively in Assam and Orissa and it decreased to 1.8%
and 11.4% respectively by D7. On D14 only one patient
Flow chart – LPF – Late Parisitological Failure; LCF – Late Clinical Failureigure 2
Flow chart – LPF – Late Parisitological Failure; LCF – Late Clinical Failure.Page 4 of 8
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without gametocytes except the one who had treatment
failure on D7 in Orissa. Two patients who reported with
recurrent parasitaemia were treated with AS+SP in stand-
ard doses as recommended in the National Drug Policy.
Out of these two treatment failure cases in Orissa, geno-
typing using msp-1 and msp-2 confirmed one of them as
reinfection and one as recrudescence. This led to PCR cor-
rected cure rates of 98.6% in Orissa. The cumulative risk
of failure (PCR corrected) by Kaplan Meier analysis was
0.014 (95% CI 0.002–0.097) in Orissa while it was zero
in Assam. The response was similar in all age categories
and the only patient who had recrudescence on D7 was a
seven year-old child, weighing 11 kg. The parasite count
on D7 was 48/μl (asexual parasites with gametocyte count
of 192/μl) in this patient. PCR analysis confirmed that it
was a single clone infection and D0 and D7 samples dis-
played the matching allele bands indicating a case of
recrudescence. Molecular analysis of pfmdr1 revealed 86Y
in both D0 and D7 samples of this patient. Pfcrt haplotype
as determined by DNA sequencing was C72M74N75K76 in
both D0 and D7 samples reiterating the case as recrudes-
cence.
Genotype analysis of the pfcrt and pfmdr1 gene
A total of 124 clinical isolates (53 from Assam and 71
from Orissa) were analysed for genetic polymorphism in
pfmdr1 and pfcrt genes. In pfmdr1, 58 isolates (26 from
Assam and 32 from Orissa) could be analyzed for both the
fragments. Fragment 1 covering codons 86 and 184 was
amplified from 91 isolates (27 in Assam and 64 in Orissa)
while only 63 isolates (36 from Assam and 27 from
Orissa) were successfully amplified and sequenced for
pfcrt region covering codons 72–76. Out of the five pfmdr1
codons analysed (N86Y, Y184F, S1034C, N1042D and
D1246Y), mutation was observed only at 86 and 184
codons while others remained wild type among all iso-
lates. There were a total of 3 different pfmdr1 alleles
among the isolates. Genotype Y86Y184S1034N1042D1246 was
more prevalent (62.06%, total n = 58) than wild type
(N86Y184S1034N1042D1246) and the single mutant
(N86F184S1034N1042D1246) alleles which were present in
31.03 and 6.89% of isolates, respectively. At codon 86,
pre-treatment carriage of N86 was 41.7% while 86Y was
58.3%. However, at codon 184 most of the isolates
showed 184Y (91.3%, total n = 91). Mutation in pfcrt was
observed at 72 (14.89% n = 9), 74(68.6%, n = 43), 75
(68.6% n = 43) and 76 (70% n = 53) codons among 63
isolates with C72I74E75T76 triple mutant allele being most
predominant (68.6%) while isolates with C72M74N75T76
were rare (1.4%). Only 14.9% isolates were found to con-
tain the wild type C72M74N75K76or double mutant
S72M74N75T76alleles.
Regional prevalence of pfmdr1 and pfcrt alleles
All the three genotypes of pfmdr1 were present in both
Assam (n = 26) and Orissa (n = 32). Single mutant
PCR uncorrected and PCR corrected cure rates by per pro-tocol analysisFigure 3
PCR uncorrected and PCR corrected cure rates by 
per protocol analysis.
Table 2: Demographic and clinical characteristics of patients on inclusion
State (District) Assam (Kamrup) Orissa (Keonjhar)
No. of cases enrolled 53 71
Gender ratio (M/F) 36/17 32/39
Age category Mean ± SD Mean ± SD
<5 Year 3.3 ± 0.5 (n = 3) 3.2 ± 0.9 (n = 13)
5–15 8.6 ± 2.7 (n = 24) 8.2 ± 2.8 (n = 28)
Adult 29.7 ± 11.2 (n = 26) 25.3 ± 10.2 (n = 30)
All 15.0 ± 14.3 (n = 53) 11.1 ± 12.14 (n = 71)
% patients with fever on D0 66.04 100
Parasitaemia/μl (Geometric Mean) 7922.7 7653.3
Range 1000 – 76190 1040 – 99200Page 5 of 8
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both regions as compared to N86Y184S1034N1042D1246 and
N86F184S1034N1042D1246 genotypes (Table 3). pfcrt triple
mutant (C72I74E75T76) genotype was present in highest
proportion in both Assam (72.2% n = 36), and Orissa
(64.2%, n = 27). Proportionately wild type
C72M74N75K76genotype was more prevalent in Orissa
(25%) than in Assam (8.3%). Also single mutant
C72M74N75T76 was found only in Orissa (3.5%).
S72M74N75T76 genotype was present in both Assam
(19.4%) and Orissa (7.1%).
Paired sample analysis
In this study, two treatment failure cases were recorded in
Orissa and msp-1 and msp-2 genotyping confirmed one of
them as reinfection and other as a recrudescence. Another
case in Orissa, reported on D38 with positive parasitaemia
which was reinfection and as such not included in analy-
sis of 28 day failure rate. Out of these cases of reinfection,
one had Y86Y184S1034N1042D1246 and another showed
N86Y184S1034N1042D1246 haplotype at D0. However, on the
day of failure, both cases had different pfmdr1 genotypes,
N86Y184S1034N1042D1246 (D28) and
N86F184S1034N1042D1246 (D38) respectively (Table 3). Gen-
otype analysis of pfcrt at D0, for both isolates was
C72I74E75T76 but in failure case at D28 it was
C72M74N75T76 and at D38 it was mixture of C72M74N75T76
and C72I74E75T76 genotypes. In the recrudescence case, the
genotype for both pfmdr1 and pfcrt at D0 and at D7
remained the same i.e.Y86Y184S1034N1042D1246 and
C72M74N75K76 respectively (Table 4).
Discussion
In India, ACT has been introduced in all Primary health
centers (PHCs) of 117 high risk districts and 256 chloro-
quine resistant PHCs of 48 districts for the treatment of
falciparum malaria. The ACT recommended by the
National Programme is AS+SP, which is highly effective
but available as blister pack and not a fixed dose formula-
tion. AL is the only fixed dose combination that has been
approved for marketing recently and there is no data on
safety and efficacy of recommended six-dose regimen in
India. The present study was carried out to assess the effi-
cacy of AL in India and its correlation with molecular
markers. The drug was well tolerated and produced rapid
parasite clearance. Majority of patients, viz. 79.2 and
90.1% in Assam and Orissa respectively, were free of par-
asites within 48 h and cure rates were high at these sites
where chloroquine resistance is high.
A case of treatment failure on D7 has been observed for
the first time with the six-dose regimen of AL in the study.
There is only one earlier report of failure on D9 in a three-
year old child in Comoros [12]. Treatment failure to any
drug can be due to true resistance of parasite to drug or
inadequate blood levels due to low absorption or altered
pharmacokinetics of the drug. Molecular genotyping con-
firmed recrudescence, which was reiterated by pfcrt haplo-
Table 3: Regional distribution of pfcrt and pfmdr1 genotypes
Isolates, no. (%)
Genes Genotypes Assam (n = 26) Orissa
(n = 32)
Total (n = 58)
pfmdr1
Wild-type N86Y184S1032N1042D1246 7 (26.9%) 11 (34.3%) 18 (31.03%)
Single-mutant Y86Y184S1032N1042D1246 18 (69.2%) 18 (56.2%) 36 (62.06%)
Single-mutant N86F184S1032N1042D1246 1 (3.8%) 3 (9.3%) 4 (6.89%)




Wild-type C72M74N75K76 3 (8.3%) 7 (25.9%) 10 (15.8%)
Single-mutant C72M74N75T76 - 1 (3.7%) 1 (1.5%)
Double-mutant S72M74N75T76 7 (19.4%) 2 (7.4%) 9 (14.2%)
Triple-mutant C72 I74E75T76 26 (72.2%) 17 (62.9%) 43 (68.2%)
Note: Mutated amino acids are in boldPage 6 of 8
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haplotype in both D0 and D7 Samples. In vivo exposure to
AL props up the selection of pfmdr1 86N in new inocula-
tion and is suggested to be associated with tolerance to
lumefantrine [4]. However, in this case presence of 86Y
ruled out the true drug resistance as the cause of treatment
failure. Complete intake of therapeutic dose was ensured
by supervised therapy, though blood drug concentration
was not determined. The dose was also adequate accord-
ing to body weight of the child, which was low for his age
indicating malnutrition. Artemether component is
absorbed rapidly, while absorption of lumefantrine is
dependent on co-administration with fat. As fatty food is
generally not well tolerated by febrile children, the drug
was administered with biscuits and water. Malabsorption
syndrome, which could lead to incomplete absorption of
drug in the patient, was excluded by negative history of
chronic diarrhoea or vomiting. Altered distribution or
increased clearance may have led to sub-therapeutic levels
of drug leading to treatment failure. As such malnutrition
has been shown to cause larger volume of distribution
causing lower plasma concentration and hypoalbuminae-
mia may also lead to increased levels of unbound drug
resulting in increased metabolic clearance [2].
The likelihood of resistance to AL in India is low, since the
drug is not included in the National Drug Policy for the
treatment of malaria till date. However, recently, market-
ing permission has been given to few companies. In this
scenario, the reappearance of parasites on D7 led us to
investigate the possible misuse of the drug. Six brands of
AL were available in the town since 2006 and the drug was
dispensed without prescription by the local chemists. Dis-
cussion with doctors also revealed that drug was being
prescribed in various private clinics. This case highlights
the need to study the kinetics of drug in malnutrition. In
addition, over the counter availability and possible mis-
use of the drug raises concern of accelerating resistance in
near future to one of the valuable ACT.
In addition to clinical outcomes, pre-treatment prevalence
of pfmdr1 and pfcrt alleles in Indian P. falciparum isolates
was also studied. High prevalence of 184Y (93.3%) in pre-
treatment samples was observed. Genotypes indicate that
majority of isolates carried Y86Y184S1034N1042D1246
(62.06%) followed by N86Y184S1034N1042D1246 (31.03%)
and only 6.8% isolates had
N86F184S1034N1042D1246genotype. In pfmdr1 mutation at
only codons 86 and 184 have been found which is similar
to earlier report [13].
Previous studies with AL in Africa [14] showed higher
baseline predominance of Y86Y184Y1246 genotype of
pfmdr1, and selection of N86F184D1246 genotype after AL
treatment. Results of the present study indicate baseline
prevalence of Y86Y184D1246 haplotype in India. Also 6.8%
pre-treatment isolates that carry N86F184D1246genotype
were drug sensitive. Two clinical failure cases were classi-
fied as reinfection which selected
N86Y184S1034N1042D1246and Y86Y184S1034N1042D1246 haplo-
type, whereas one case of recrudescence has not shown
any change in pfmdr1 haplotype, i.e. it remained as
Y86Y184S1034N1042D1246. Since there were very few clinical
failure cases, it is difficult to conclude any specific selec-
tion of a particular genotype after AL treatment. Presence
of pfcrt C72I74E75T76 genotype in highest proportion indi-
cates the preexistence of high level of CQ resistance
among the parasite population [11].
The main limitation of the study is that co-relation of
molecular markers with treatment failure was difficult due
to very low number of treatment failure cases and drug
concentration in this case could not be done.
Considering the prevalence of molecular markers of resist-
ance to sulphadoxine/pyrimethamine (SP) especially in
north-eastern states in India [15], the non-availability of
fixed dose combination of AS+SP and the high efficacy of
AL, the latter can be considered as a good alternative
Table 4: Genotype analysis of pfmdr1 and pfcrt in reinfection vs. recrudescences after AL treatment
Genotype at Day 0 Genotype at Day of failure
Isolate Day failure pfmdr1 pfcrt pfmdr1 pfcrt
Reinfection (n = 2)
1 Day28 Y86Y184S1032N1042D1246 C72I74E75T76 N86Y184S1032N1042D1246 C72M74N75T76
2 Day38 N86Y184S1032N1042D1246 C72 I74E75T76 N86F184S1032N1042D1246 C72M74N75T76/C72 I74E75T76
Recrudescence (n = 1)
1 Day7 Y86Y184S1032N1042D1246 C72M74N75K76 Y86Y184S1032N1042D1246 C72M74N75K76
Note: Mutated amino acids are in boldPage 7 of 8
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option as ACT for the treatment of falciparum malaria in
India. However, adequate care should be taken to ensure
compliance and good absorption of the drug.
Lack of correlation of molecular markers for resistance
with clinical outcome makes it difficult to monitor and
predict resistance to this combination. Efficacy of AL
needs to be monitored using in vivo studies and further
molecular studies may help in developing markers to pre-
dict impending resistance.
Conclusion
Artemether-lumefantrine is safe and effective drug for the
treatment of uncomplicated falciparum malaria in India.
The efficacy of this ACT needs to be carefully monitored
periodically since the treatment failures can occur due to
resistance as well as subtherapeutic levels due to inade-
quate absorption especially if not administered with fat or
in malnutrition. As such malnutrition and poor uptake of
fat is common in poor tribal population. However, since
AL is the only fixed combination available in India till
date, it can be a viable alternative to AS+SP for the treat-
ment of uncomplicated falciparum malaria.
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